High-throughput analysis of the RNA-induced silencing complex in myotonic dystrophy type 1 patients identifies the dysregulation of miR-29c and its target ASB2 by Cappella, Marisa et al.
Cappella et al. Cell Death and Disease  (2018) 9:729 
DOI 10.1038/s41419-018-0769-5 Cell Death & Disease
ART ICLE Open Ac ce s s
High-throughput analysis of the RNA-
induced silencing complex in myotonic
dystrophy type 1 patients identifies the
dysregulation of miR-29c and its target
ASB2
Marisa Cappella1, Alessandra Perfetti2, Beatrice Cardinali1, Jose Manuel Garcia-Manteiga3, Matteo Carrara2,
Claudia Provenzano1, Paola Fuschi2, Rosanna Cardani4, Laura Valentina Renna4, Giovanni Meola4,5,6,
Germana Falcone1 and Fabio Martelli2
Abstract
Myotonic dystrophy type 1 (DM1) is a multi-systemic disorder caused by abnormally expanded stretches of CTG DNA
triplets in the DMPK gene, leading to mutated-transcript RNA-toxicity. MicroRNAs (miRNAs) are short non-coding RNAs
that, after maturation, are loaded onto the RISC effector complex that destabilizes target mRNAs and represses their
translation. In DM1 muscle biopsies not only the expression, but also the intracellular localization of specific miRNAs is
disrupted, leading to the dysregulation of the relevant mRNA targets. To investigate the functional alterations of the
miRNA/target interactions in DM1, we analyzed by RNA-sequencing the RISC-associated RNAs in skeletal muscle
biopsies derived from DM1 patients and matched controls. The mRNAs found deregulated in DM1 biopsies were
involved in pathways and functions relevant for the disease, such as energetic metabolism, calcium signaling, muscle
contraction and p53-dependent apoptosis. Bioinformatic analysis of the miRNA/mRNA interactions based on the RISC
enrichment profiles, identified 24 miRNA/mRNA correlations. Following validation in 21 independent samples, we
focused on the couple miR-29c/ASB2 because of the role of miR-29c in fibrosis (a feature of late-stage DM1 patients)
and of ASB2 in the regulation of muscle mass. Luciferase reporter assay confirmed the direct interaction between miR-
29c and ASB2. Moreover, decreased miR-29c and increased ASB2 levels were verified also in immortalized myogenic
cells and primary fibroblasts, derived from biopsies of DM1 patients and controls. CRISPR/Cas9-mediated deletion of
CTG expansions rescued normal miR-29c and ASB2 levels, indicating a direct link between the mutant repeats and the
miRNA/target expression. In conclusion, functionally relevant miRNA/mRNA interactions were identified in skeletal
muscles of DM1 patients, highlighting the dysfunction of miR-29c and ASB2.
Introduction
DM1 (OMIM #160900) is a chronic, slowly progres-
sing multi-systemic disease, with symptoms that
include loss of muscle strength, myotonia, excessive
fatigue, cardiac conduction defects, cataracts, insulin
resistance and, in the most severe forms, cognitive
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impairment1–3. DM1 is caused by a dynamic expansion
of CTG repeats, ranging from 50 to several thousands,
in the 3′ untranslated region of the dystrophia myoto-
nica protein kinase (DMPK) gene4. Characteristic
molecular features of the disease have been associated
with a toxic RNA gain of function of the CUG expan-
sions. Expanded CUG repeats have been demonstrated
to be toxic per se in several cell types and animal
models5–7, disrupting pre-mRNA alternative splicing8.
Mutant CUG repeats accumulate into distinctive foci
within muscle nuclei and lead to dysregulation of RNA-
binding proteins such as MBNL1 and CELF1. Both
MBNL1 and CELF1 regulate critical alternative splicing
transitions during heart and skeletal muscle develop-
ment, which are dysregulated in DM18–11.
Adding complexity to the molecular pathology of
DM1, several other disease mechanisms have been
recently found, including microRNA (miRNA) dysre-
gulation12–16. miRNAs are short non-coding RNAs,
which regulate gene expression by decreasing their target
mRNA levels, or by blocking their translation17–19.
miRNAs are generated by longer precursors and mature
miRNAs are the product of the sequential action of
Drosha and Dicer endonucleases. miRNA/target interac-
tion is mediated by the RNA-Induced Silencing Complex
(RISC), of which AGO2 is an obligatory component. The
levels of a subset of miRNAs, both muscle specific (miR-
206, miR-1) and not (miR-335, miR-29b, miR-29c, and
miR-33), have been found to be deregulated in DM112–16.
For miR-1 and miR-206, contrasting data have been
reported, probably depending on the low numerosity of
DM1 patients studied and the disease severity, as well as
the type of skeletal muscle analyzed. Importantly, we also
found that intracellular distribution of miR-1, miR-133b
and miR-206 was severely altered15. This is likely to be
functionally important, since the expression of at least
some of the corresponding targets was also modified.
In a DM1 cell model, it has been shown that transcripts
containing long CUG-repeat hairpins are substrates of the
ribonuclease Dicer and that the fragments generated can act
as endogenous siRNAs, triggering a downstream silencing
effect20. However, it is still unknown whether CUG-repeated
short sequences are functionally active in vivo. Finally,
DMPK transcripts containing expanded CUGs may also act
as molecular sponges for miRNAs with CAG repeats in their
seed regions21.
Thus, while it seems clear that miRNA pathway is
disrupted in DM1, the functional implications of this
dysregulation require further investigation. To identify
“functional” miRNAs, actually engaged in mRNA/target
inhibitions relevant for DM1 disease mechanisms, we
analyzed RISC-associated RNAs in muscle biopsies
derived from DM1 patients compared to healthy
individuals.
Results
Sequencing of the RNAs associated to the RISC complex of
DM1 skeletal muscles
In order to characterize the deregulation of the RNAs
associated to the RISC complex in the skeletal muscle of
DM1 patients, RISC complexes were immunopurified and
both miRNAs and mRNAs were analyzed by RNA-
sequencing (RNA-Seq). A schematic representation of
the experimental plan is shown in Fig. 1a.
Triplicate biceps brachii biopsies were harvested from 3
DM1 patients and from three individuals not affected by
neuromuscular disorders. One biopsy was used for his-
tological evaluation, one for total RNA extraction and one
for RISC immunoprecipitation (RISC-IP). Clinical fea-
tures of both DM1 patients and controls (CTRs) are
summarized in Supplementary Tables S1 and S2. Histo-
logical analysis of DM1 biopsies displayed typical disease
hallmarks such as centrally nucleated and atrophic myo-
fibers, and nuclear clumps, in the absence of overt fibrosis,
as previously described (Supplementary Figure S1 22).
RISC-IPs were performed with antibodies to Ago2, a core
component of the RISC17, 18 and the associated RNAs were
extracted. As control for effective Ago2/RNA co-immuno-
precipitation, an aliquot of the extracted RNA was analyzed
by qPCR for the enrichment of small RNAs (miR-1 and miR-
221), as well as of long RNAs (CDKN1B and FOS mRNAs),
compared to IP performed with control antibodies (Supple-
mentary Figure S2). As expected, U6 small nuclear 1 (RNU6-
1) that does not associate to the RISC, displayed no
enrichment.
RNA derived from the RISC-IP samples was sequenced
measuring both small and long RNAs, allowing the
identification of 201 miRNAs as well as of 12,976 between
mRNAs and lncRNAs. As reference, small RNAs were
sequenced from total RNAs derived from the same
patients and CTRs used for RISC-IPs.
Data from bioinformatic analysis identified miRNAs and
mRNAs that were differentially enriched or depleted in DM1
RISCs compared to RISCs derived from CTR biopsies. Spe-
cifically, 11 and 37 miRNAs were found selecting miRNAs
for adjusted p-values ≤ 0.05 and 0.10, respectively (Fig. 1b and
Supplementary Table S3). Of note, most miRNAs differen-
tially modulated in the RISC of DM1 patients displayed
similar trends, but failed to reach statistical significance, in
total RNA counterparts (Supplementary Table S4), con-
firming the additional insight provided by the analysis of
RISC-associated RNAs. Only two miRNAs behaved differ-
ently in total RNA-Seq: miR-1301 was not detected and miR-
182 displayed very similar levels in DM1 and CTR total
RNAs.
When RISC-associated mRNAs were analyzed, 35 and 103
mRNAs were identified as differentially enriched or depleted
between DM1 and CTR for adjusted p-values of ≤0.05 and
0.10, respectively (Fig. 1c and Supplementary Table S5).
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Next, we investigated the biological functions associated to
the RISC-mRNAs differentially modulated in DM1 patients.
To this aim, enriched biological processes and pathways were
identified by ClueGO23. Supplementary Figure 3 shows
enrichments in terms related to energetic metabolism, cal-
cium signaling, muscle contraction, and p53-dependent
apoptosis. Many of these functions have been shown to be
deregulated in DM11–3, suggesting an involvement of the
RISC function in the disease mechanisms.
CUG-containing RNA oligomers are undetectable in the
RISC complex of DM1 skeletal muscles
It has been shown in a DM1 cell model that transcripts
containing long repeat hairpins are substrates of the ribo-
nuclease Dicer, yielding fragments that can act as siRNAs20.
Thus, we tested whether CUG-oligomers were enriched in
the RISC complexes derived from skeletal muscle biopsies
of DM1 patients. It was found that CUG-oligomers were
not detectable in the dataset obtained by sequencing the
small RNAs associated to the RISC in DM1 patients.
However, these triplet-containing RNAs were absent also in
the dataset obtained from the sequencing of total small
RNAs, suggesting a low representation of the CUG repeats
in the libraries or a low sequencing efficiency.
Given the technical shortcomings of the RNA-sequencing
technique, we attempted to measure by qPCR whether
CUG-containing oligomers were enriched in the RISC of
DM1 skeletal muscles. To this aim, total RNA was poly-
adenylated and reverse transcribed with a poly(T) adapter
into cDNAs, followed by qPCR amplification (Supplemen-
tary Figure S4a)24. As expected, CUG-containing RNAs
were readily detectable in total RNAs extracted from DM1
muscles. However, the opposite was true for RISC-IP
derived RNAs, indicating a low incorporation efficiency of
CUG-containing RNAs in the RISC of DM1 skeletal mus-
cles (Supplementary Figure S4b, c).
Identification of miRNA/target mRNA pairs
To perform a comprehensive analysis of the miRNA/
mRNA interactions based on the RISC enrichment profiles,
we took advantage of the miRTrail webserver25. To increase
stringency, only miRNAs and mRNAs displaying an adjusted
p-value of 0.05 were considered for target identification.
Both positive and negative miRNA/mRNA correlations
were considered, in keeping with the dual modality of
miRNA function: translational control and mRNA degrada-
tion18, 19. Indeed, increased or decreased levels of a miRNA
should lead to concordant increased or decreased target
mRNA recruitment to the RISC for those miRNA/mRNA
couples where the miRNA inhibitory role is mainly at the
translational level. However, for those miRNA/mRNA pairs
leading to efficient mRNA destabilization, increased or
decreased miRNA incorporation in the RISC can lead to
counter-regulation of the target levels and, consequently, its
Fig. 1 Experimental strategy and RISC-associated miRNAs and
mRNAs. a Experimental plan outline. b, c Volcano plot of differentially
modulated miRNAs and mRNAs, revealed by RISC-associated RNA-
sequencing. miRNAs (b) and mRNAs (c), differentially modulated in
RISC complex of DM1 patients compared to CTRs. Red dots represent
miRNAs and mRNAs displaying statistically significant differences (FDR
< 0.1; DM1, n= 3; CTR, n= 3). miRNAs with mRNA targets differentially
modulated in the RISC, and validated mRNAs are identified by name
in b and c, respectively
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depletion or enrichment in the RISC, respectively. Table 1
shows the miRNA/mRNA pairs identified.
To validate these findings, new DM1 patients and CTRs
were recruited and biopsies analyzed (Supplementary
Tables S1 and S2). Given the low RNA amount that is co-
immunoprecipitated with the RISC, miRNAs, and target
mRNAs, selected on the basis of their relevance to
disease-related pathways, were tested by qPCR only in a
sample subset. However, each RNA was assayed in at least
10 samples (5 DM1 patients and 5 CTRs). Data are shown
in Fig. 2a and b as heatmaps and in Fig. 2c and d and
Supplementary Figure S5 as dot plots. A global agreement
Table 1 miRNA/target mRNA couples enriched (in red) or depleted (in green) in the RISC of DM1 patients
Fig. 2 Modulation of miRNAs and mRNAs in skeletal muscle tissue. a, b Comparison between RNA-Seq results (DM1, n= 3; CTR, n= 3) and qPCR
validation (DM1, n ≥ 5; CTR ≥ 5) in RISC-IP samples of DM1 compared to CTR subjects. Data are represented in Log2 scale, (−ΔΔCt), referred to CTRs.
Upregulated and downregulated genes are indicated in red and in green, respectively. a miRNAs; miR-381 was not detectable by qPCR in both input
and IP RNAs; b mRNAs; mRNA RNA-Seq of input RNA was not performed. c Dot plots of miR-29c and ASB2 mRNA validation experiments. RISC-IP
associated RNAs (IP) and INPUT RNAs obtained from biopsies of DM1 patients vs healthy subjects (CTR) were analyzed by qPCR and normalized to
miR-181a and RPL23 mRNA, respectively. Values are indicated as −1*ΔΔCt fold changes (log2FC). Average and error bars are also indicated (CTR n ≥ 5;
DM1 n ≥ 5; *P < 0.05; **P < 0.01). White circles: CTR; black circles: DM1
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between RNA-Seq and qPCR data was observed, although
statistical significance was not reached in all cases, pos-
sibly due to patient variability and low numerosity. miR-
381 was undetectable by qPCR in RISC-IPs and could not
be tested. ACTN3 (Alpha-actinin 3, Skeletal muscle) was
not targeted by the dysregulated miRNAs and was
included as a muscle-specific control. Eventually, qPCR
validation was obtained for 2 miRNAs (miR-29c and miR-
411) and for 6 mRNAs: SESN3 (Sestrin 3), ACTC1 (Actin,
Alpha, Cardiac muscle I), FST (Follistatin), WEE1 (WEE1
G2 Checkpoint kinase), ERBB3 (Erb-B2 Receptor Tyrosine
kinase 3), and ASB2 (Ankyrin Repeat and SOCS Box
Containing 2). Interestingly, qPCR analysis of input and
RISC-associated mRNAs and miRNAs revealed a different
or even opposite modulation in some cases, supporting
the relevance of RISC-associated RNA analysis, compared
to analysis of total RNA, to identify functionally relevant
miRNA/mRNA target pairs.
miR-29c and ASB2 deregulation in DM1 cell models
Given the role of miR-29c and ASB2 in skeletal muscle
hypertrophy26 and in fibrosis27, we decided to study this
miRNA/target couple in more detail.
To this aim, we took advantage of DM1 and CTR
myogenic cell lines that we recently generated from
patient-derived dermal fibroblasts28. These cells exhibited
the DM1-typical ribonuclear aggregates containing CUG
repeats (Supplementary Figure S6a); upon induction that
triggers MyoD translocation to the nucleus, both CTR
and DM1 cells differentiated efficiently (Supplementary
Figure S6b).
qPCR analysis of RISC-associated miR-29c in CTR and
DM1 differentiated myotubes, confirmed a significant
miRNA downregulation in DM1 samples (Fig. 3a), in
agreement with the results obtained in skeletal muscle
biopsies. In order to validate ASB2 as a target of miR-29c,
we investigated whether there was a correlation between
ASB2 and miR-29c expression both in CTR and DM1 cell
models. Interestingly, analysis of miR29c and its predicted
target protein ASB2 during myoblast differentiation,
showed an inverse correlation between miR-29c accu-
mulation and ASB2 transcript/protein levels in DM1
compared to CTR cells at all timepoints (Fig. 3b).
Next, we tested whether there was a direct link between
miR-29c/ASB2 deregulation and CTG-repeat expansion.
To this aim, we assayed DM1 myogenic cell clones in
which the toxic mutant CTG-repeats were removed by
CRISPR/Cas9 gene editing system28. These clones were
negative for ribonuclear foci, exhibited normal splicing,
differentiated upon MyoD induction, and formed myo-
tubes, similarly to CTR myoblasts28. A significant rescue
of both miR-29c and ASB2 expression was observed in
these clones, compared to non-edited clones retaining full
expansion (Fig. 3c).
Along with myofibers, another major cell component of
skeletal muscles are fibroblasts. Indeed, fibrosis is a dis-
ease hallmark in end-stage DM1 patients (Supplementary
Figure S7)1–3. Thus, primary fibroblasts were derived
from both DM1 and CTR skeletal muscle samples and the
cells cultured in vitro.
As expected, these cells were negative for desmin and
positive for α-smooth muscle actin and vimentin (Sup-
plementary Figure S8). In keeping with skeletal muscle
biopsies, miR-29c was decreased and ASB2 mRNA was
increased in DM1 muscle fibroblasts (Supplementary
Figure S9).
Therefore, in vitro experiments confirmed that ASB2
mRNA/protein were upregulated in DM1 cells whereas
miR-29c was down-modulated.
miR-29c targets ASB2 directly
To provide further evidence of a direct miR-29c/ASB2
regulation, we tested whether miR-29c overexpression
decreased ASB2 protein levels. Thus, fibroblasts were
transfected with a miR-29c expressing plasmid and ASB2
was assayed. Figure 4a shows that, indeed, miR-29c
expression decreased ASB2 protein levels as much as
those of CDC42, a bona fide miR-29c target29.
To confirm that miR-29c targets ASB2 directly, miR-29c
pairing-sites or their mutated versions and the immedi-
ately surrounding sequences contained in ASB2 were
cloned downstream of a luciferase open reading frame.
The luciferase activity of these constructs was evaluated
following the overexpression of either miR-29c or a
scramble sequence in HEK-293 cells. Figure 4b shows that
miR-29c inhibited luciferase expression from the reporter
constructs containing an intact miR-29c binding site,
whereas this effect was prevented by the mutation of the
seed-complementary nucleotides. These data demonstrate
that miR-29c inhibits ASB2 expression directly.
Discussion
Different studies highlighted miRNA dysregulation in
DM112–16. However, the functional consequences of this
dysregulation are far from being elucidated. In this inves-
tigation, we analyzed both miRNAs and mRNAs associated
to the RISC in muscle biopsies derived from DM1 patients
and CTRs. By this approach, we identified, in an unbiased
manner, miRNA/target interactions that were altered in
DM1. Moreover, the analysis of patient-derived skeletal
muscle biopsies facilitated the identification of pathways
and functions potentially relevant for DM1 disease
mechanisms. As a confirmation of the additional insight
provided by this approach, most miRNA dysregulations
identified in the RISC did not reach statistical significance
when total RNA was analyzed. It is worth noting that, due
to the complexity of the RISC-IP/RNA-Seq approach, we
had to start from a limited number of biopsies, possibly
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missing some modulated miRNAs. While this work gives an
important contribute to our understanding of miRNA role
in DM1, future profiling of a higher patient number might
allow to identify other miRNA/mRNA couples displaying
higher variability.
The analysis of RISC-associated RNAs was also
important to understand the functional relevance of
CUG-oligomers originating from the Dicer activity on
DMPK-mutated transcripts20. Indeed, while small CUG-
containing RNAs were readily detectable in total RNAs
Fig. 3 Expression of miR-29c and ASB2 in myogenic cells. a qPCR analysis of miR-29c in RISC complexes derived from two CTR and two DM1 cell
lines allowed to differentiate for 5 days. Levels of miR-29c in both INPUT and IP were normalized on miR-181a levels, and shown as fold change of
DM1 vs CTR, referred as 1 (n= 6; *P < 0.05). b Expression of miR29c and ASB2 in CTR and DM1 undifferentiated myogenic cells (T0) and myogenic
cells induced to differentiate for 3 and 5 days (T1 and T2, respectively). Expression of miR-29c and ASB2 mRNA was analyzed by qPCR (top and middle
charts), normalized for expression of miR-16 and RPL23, respectively, while ASB2 protein expression was measured by western blot (bottom chart and
gel image of a representative experiment), normalized to vinculin (VCL) expression. DM1 values were first normalized to CTR, referred as 1, for each
experiment and then the average value and standard error of DM1 fold change was calculated (n ≥ 4; *P < 0.05; **P < 0.01; ***P < 0.001). c Expression
of miR-29c and ASB2 protein in CRISPR/Cas9 treated clones, either maintaining CTG expansions (CTG+, average values of 2 clones) or with full
deletion of repeat expansions (CTG−, average values of 2 clones), induced to differentiate for 2 days. Values were normalized for expression of miR-16
and vinculin, respectively, and shown as fold change of CTG− clones relative to CTG+ clones referred as 1. (n ≥ 3; *P < 0.05; ***P < 0.001). A
representative western blot analysis of ASB2 protein in CRISPR-Cas9-edited clones and in untreated DM1 and CTR cells is shown
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extracted from DM1 muscles, we did not find evidence of
their association to the RISC, questioning their proposed
role on target inhibition by RISC-mediated RNAi20.
The identification of deregulated mRNAs associated to
the RISC was also very informative. As discussed below,
this facilitated the identification of relevant targets of the
dysregulated miRNAs. Moreover, a broad picture of the
transcriptomic alterations in DM1 was provided. It is
likely that many of the identified deregulations were not
due only to altered recruitment by the miRNAs, but also
to the combined action of different mechanisms, such as
altered transcription. However, this analysis allowed the
identification of pathways and functions relevant for the
disease, such as energetic metabolism, calcium signaling,
muscle contraction, and p53-dependent apoptosis1–3.
Bioinformatic analysis of the miRNA/mRNA interac-
tions based on the RISC enrichment profiles, identified 24
miRNA/mRNA correlations. It is worth noting that, while
miR-29c15, 16 and miR-38130 alterations were identified
before, all the other miRNAs identified had escaped pre-
vious studies based on total RNA analysis.
The miRNAs deregulated in DM1 and their targets are
involved in muscle damage and disease. Indeed, miR-15a
targets ACTC1, a characterizing gene for the enrichment
of the “muscle contraction” categories among the RISC-
associated mRNAs.
miR-155 impairs myogenesis31, 32; moreover, its targets
TSPAN13 and LRP1B are also targeted by miR-222 and
miR-381, respectively, suggesting a potential cooperative
action between these miRNAs.
miR-22 is enriched in both cardiac- and skeletal mus-
cles, is upregulated during myocyte differentiation and is a
critical regulator of cardiomyocyte hypertrophy33. More-
over, ERBB3, a target of miR-22, was the characterizing
gene that started the enrichment of the calcineurin-NFAT
signaling cascade among the RISC-associated mRNAs34.
We previously identified miR-222 as a critical regulator of
skeletal muscle cell differentiation and maturation35, 36.
Moreover, miR-222 target Myosin Light Chain Kinase 2
(MLCK2) was the characterizing gene for the enrichment of
the “skeletal muscle development” and of the “muscle con-
traction” categories among the RISC-associated mRNAs.
MiR-381 was previously identified by our group
as increased in DM230. MiR-411 targets FST, a physiolo-
gical myostatin inhibitor promoting skeletal muscle
hypertrophy37.
We have characterized in more detail the dysregulation of
the miR-29c/ASB2 couple and shown that ASB2 mRNA is a
direct target of miR-29c. Moreover the deletion by genome
editing of the CTG amplifications in a DM1 cell model
rescued miR-29c/ASB2 dysregulation, linking miR-29c
regulation to the presence of CTG amplifications. Further
studies are needed to investigate the molecular mechanisms
inducing miR-29c downregulation in DM1. Of note, a
miRNA-sequestration mechanism by CUG repeats has
been proposed, although no evidence was provided for miR-
29c specifically21.
Fig. 4 Validation of ASB2 as a direct target of miR-29c. a
Undifferentiated myogenic cells were transfected with miR-29c- or
scramble (SCR)-expression vectors and the levels of ASB2 and CDC42
were analyzed by western blotting. A representative blot is shown.
Vinculin (VCN) is shown as loading control. The histogram shows the
quantitation of the expression levels of ASB2 and CDC42 normalized
to vinculin in cells expressing miR-29c vs cells expressing scramble,
referred as 1 (n= 3; *P < 0.05; ***P < 0.001). b HEK-293 cells were
transfected with empty Firefly luciferase reporter vector (pMIR-
REPORT) or derived constructs containing either an intact miR-29c-
binding site (wt), or a mutated miR-29c-binding site (mut) in ASB2 3′
UTR target region. Each plasmid was co-transfected with a plasmid
encoding renilla luciferase along with miR-29c- or scramble (SCR)-
expression vectors. Activities of each pMIR-REPORT construct were
normalized first to Renilla luciferase and then to empty vector
activities. Luciferase (luc) activity in cells transfected with miR-29c is
shown relative to activity in cells transfected with scramble RNA,
referred as 1 (n ≥ 11; **P < 0.01)
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miR-29-family miRNAs display a crucial role in the
regulation of extracellular matrix genes and in fibrosis27,
suggesting that a similar role might be played also in
DM1. Accordingly, analysis of cell cultures derived from
DM1 patients allowed to identify decreased miR-29c
levels in both myogenic and fibroblastic cells. While
overt fibrosis was not particularly present in the ana-
lyzed proximal muscles of low-mid grade patients,
fibrosis is a DM1 disease hallmark in higher grade
patients, especially in distal muscles, such as the tibialis
anterior1–3. Further studies are necessary, but it is
tempting to speculate that decreased miR-29c levels
might be prognostic of fibrosis becoming more evident
as the disease progresses.
ASB2 is a subunit of a multimeric E3 ubiquitin-ligase
complex that mediates the degradation of cytoskeletal
components, such as filamin B38 and desmin39. Thus,
ASB2 regulates cell spreading40 and migration41.
Type 1 fiber atrophy is a histological trait characterizing
DM1 disease in the muscle22. Interestingly, ASB2 has been
shown to negatively regulate muscle mass and its repres-
sion is necessary for FST-induced muscle hypertrophy26.
Additionally, a specific ASB2 isoform, ASB2beta, is
important for muscle differentiation through the targeting
of filamin B to destruction by the proteasome38. It is
worth noting, however, that the identified miR-29c
binding site is in the 3′UTR of the ASB2 gene that is
common to alpha- and beta-ASB2 isoforms.
In conclusion, we found that the characterization of the
RNAs associated to the RISC complex allowed to identify
combinations of miRNAs and their target mRNAs altered
in DM1 patients and likely relevant for the disease.
Methods
Human cells and tissues
This study was authorized by the Institutional Ethics
Committee (miRNADM of 23.06.2015) and was conducted
in accordance with the principles expressed in the
Declaration of Helsinki, the institutional regulation, and
Italian laws and guidelines. All human specimens were
obtained after receiving written informed consent. Clinical
diagnosis of DM patients was based upon International
Consortium for Myotonic Dystrophies guidelines42, and
genetic analysis was carried out to confirm DM diagnosis,
as previously described43. CTR biopsies were derived from
subjects admitted with suspected neuromuscular disorder
of undetermined nature. CTR biopsies did not show overt
signs of muscle pathology upon on histological and
immune-histochemical examination and patients scored
negative upon genetic testing. Patient clinical features are
summarized in Supplementary Table S1. Human muscle
biopsies from biceps brachii were harvested under sterile
conditions and snap frozen in liquid nitrogen or immedi-
ately processed for histological evaluation and cell culture.
Cell cultures and transfections
All cells were incubated under a 5% CO2 atmosphere at
37°C. HEK-293 (ATCC) cells were grown in DMEM
(Sigma-Aldrich, St. Louis, MO) supplemented with 10%
FBS (EuroClone, Milan, IT). Primary skeletal muscle
fibroblasts were derived from biceps brachii biopsies by
negative selection for CD56, a myoblast marker44, as
previously described45. The cell suspensions were nega-
tively selected using magnetic microbeads (MACS, Mil-
teny Biotec, Bergisch Gladbach, DE) conjugated with anti-
CD56 antibodies, in order to separate myogenic from
primary fibroblasts. CD56-negative cells were then cul-
tured in DMEM (Sigma-Aldrich, St. Louis, MO), 15 % FBS
(EuroClone, Milan, IT).
DM1 and CTR myogenic cell lines and CUG repeats-
edited clones were previously described28. Briefly, myo-
genic cell lines were derived from human fibroblasts
immortalized and converted to myoblasts by transduction
of the TERT and inducible MYOD1 genes. Cells were
derived from two DM1 patients carrying 290 (DM1-A)
and 520 (DM1-B) CTG amplifications at diagnosis,
respectively, and from two CTR subjects (CTR-A and
CTR-B). Clones maintaining CTG expansions (CTG+
clones 5 and 9) or with full deletion of repeat expansions
(CTG− clones 7 and B9) were generated using CRISPR/
Cas9 genome editing from DM1-A myogenic cell line.
DM1 and CTR myogenic cells were propagated in
DMEM without phenol red (GIBCO, ThermoFisher Sci-
entific, Waltham, MA) supplemented with 15% FBS
(EuroClone; Milan, IT). In these conditions, no myogenic
markers were expressed. To induce myogenic differ-
entiation, cells were grown to confluency on dishes coated
with 0.5% gelatin (Sigma-Aldrich, St. Louis, MO) and
proliferation medium was replaced with differentiation
medium consisting of DMEM without phenol red sup-
plemented with 10 μg/mL insulin (Sigma-Aldrich, St.
Louis, MO), 100 μg/mL transferrin (Gibco, ThermoFisher
Scientific, Waltham, MA), and 10−7 M β-estradiol (Sigma-
Aldrich, St. Louis, MO).
For miRNA overexpression experiments, undiffer-
entiated myogenic cells were electroporated with miEx-
press™ Precursor miRNA Expression plasmid miR-29c
(HmiR0025-MR04, GeneCopoeia Inc., Rockville, MD)
and miRNA Control Vector (CmiR0001-MR04, Gene-
Copoeia Inc., Rockville, MD) according to the manu-
facturer’s instructions (1 µg of DNA for 106 cells) (Amaxa
Basic Nucleofector Kit VP1-1002, Lonza, Basel, Switzer-
land). After electroporation cells were allowed to recover
in growth medium for 3 days and then processed for
further analysis.
RISC immunoprecipitation
Two lysis protocols were used in muscle biopsies and
cultured cells: (1) skeletal muscle biopsies were cut into
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small pieces in RIP lysis buffer (Magna RIP Kit, Merck-
Millipore, Burlington, MA) and homogenized by Tissue-
Lyser (Qiagen, Hilden, Germany); (2) Cultured cells were
lysed with the following buffer: 150mM KCl, 25 mM
TrisHCl pH 7.4, 5 mM EDTA, 0.5% NP-40, 5 mM DTT, 1
mM PMSF, protease and RNAse inhibitors. For both
lysates, homogenates were quantified for protein content,
snap frozen in liquid nitrogen and stored at −80°C until
use. For both muscle tissue and cells, 50 μg of lysate were
used for total RNA analysis (INPUT RNA) and 1 mg was
immunoprecipitated with anti-Ago2 or control mouse
IgG antibodies (Abs) (RIPAb+Ago2, Merck-Millipore,
Burlington, MA), using 5 μg of antibody for 1 mg of lysate.
Immunoprecipitation was performed using the Magna
RIP Kit (Merck-Millipore, Burlington, MA) following the
manufacturer’s instructions. IgG-bound RNA (IP RNA)
was extracted from magnetic beads using TRIzol reagent
(Invitrogen, ThermoFisher Scientific, Waltham, MA).
RNA-Seq library preparation and analysis
RNA-Seq was performed on small RNAs and long RNAs
derived from RISC-IP samples, while for total RNA only
small RNAs were sequenced. For long RNAs, rRNA-
depletion and library preparation were performed follow-
ing manufacturer’s instructions for the Nugen OVATION
RNA-Seq System V2 and Nugen OVATION Ultralow
Library Systems, while for small RNA analysis, extraction
and library preparation were performed following manu-
facturer’s instructions for the TruSeq Small RNA Library
Preparation Kit, but with a higher number of PCR cycles (n
= 17), to compensate for the low amount of RNA analyzed.
An Illumina HiSeq 2500 was used to perform a paired-end
sequencing with 100 bp long reads. The average estimated
insert size for mRNA and lncRNA was 150 bp. The
sequencing protocol for small RNAs included pooling of
samples in four pools containing both IP small RNAs and
total small RNAs. After trimming of sequencing adapters
and low quality sequences (Trimmomatic), the quality was
checked with FastQC. BWA aligner was used to align small
RNA to the hg19 human genome and STAR for longRNA
reads. Coverage was measured using HTseq-count46 against
the hg19 human transcripts (Gencode) for long RNAs or the
miRBase (v19) for miRNAs. Linear Models for Microarray
Analysis (LIMMA) with the voom function was used to find
differentially overrepresented miRNAs47. RNAseq datasets
for long RNAs RISC-IP, small RNA RISC-IP and small RNA
total RNA are publicly available on Gene Expression
Omnibus (GEO) under the accession number GSE108592.
miRNA predicted targets and gene ontology analysis
miRNA predicted targets were determined using miR-
Trail tool (http://mirtrail.bioinf.uni-sb.de/upload.php)25
amongst the differentially enriched/depleted miRNAs and
mRNAs in RISC complexes.
Enrichment in GO terms from the Biological Process
tree and KEGG pathways was calculated using ClueGO23
app for Cytoscape48, set to report terms with a corrected
p-value < 0.05.
Gene expression analysis by qPCR
Total and immunoprecipitated RNAs were extracted with
TRIzol reagent (Invitrogen, ThermoFisher Scientific, Wal-
tham, MA). For mRNA analysis, retro-transcription was
performed with the SuperScript IV Reverse Transcriptase
(ThermoFisher Scientific, Waltham, MA) using oligo (dT)
and random primers for cultured myoblasts and with
Ovation qPCR system (Nugen, San Carlo, CA) for human
biopsies. Specific primers for mRNA analysis by qPCR are
shown in Supplementary Table 2. Power SYBR Green PCR
master mix (Applied Biosystems, ThermoFisher Scientific,
Waltham, MA) was used to analyze mRNAs. Results were
normalized with respect to RPL23 expression. miRNA levels
were determined using the TaqMan MicroRNA Assays
(Applied Biosystems, ThermoFisher Scientific, Waltham,
MA) and samples were normalized to miR-181a expression
in experiments from muscle biopsies, since this miRNA was
equally expressed in DM1 and CTR RNAs according to
RNAseq. Total miR-29c levels in DM1 and CTR cell cul-
tures were instead normalized to similarly expressed miR-
16, as previously reported15 and as assessed in set up
experiments (not shown). For both miRNAs and mRNAs,
qPCR was performed using an Applied Biosystem StepO-
nePlus or 7500 Fast Real-Time PCR System; relative
expression was calculated using the comparative Ct method
(2−ΔΔCt).
qPCR analysis of small repeated RNAs
Total RNAs and immunoprecipitated RNAs were poly-
adenylated in vitro using the Poly(A) Tailing Kit (Applied
Biosystems, ThermoFisher Scientific, Waltham, MA) fol-
lowing the manufacturer’s instructions. Samples were
then annealed with an oligo(dT)-adaptor primer (Sup-
plementary Table S6) prior to retro-transcription, per-
formed with the SuperScript III Reverse Transcriptase
(Invitrogen, ThermoFisher Scientific, Waltham, MA).
Specific primers recognizing CTG triplets and the adaptor
(Supplementary Table S6) allowed the amplification of
specific products by PCR, performed using the GoTaq
Flexi DNA polymerase (Promega, Madison, WI). PCR
products were sequenced using the reverse adaptor pri-
mer. Primer synthesis and sequencing were performed by
Eurofins Scientific (Luxembourg, Luxembourg).
RNA FISH and immunofluorescence stainings
Cells were fixed with 2% formaldehyde and subjected to
FISH using a (CAG)6 probe labelled with Texas Red at the
5′ end (IDT, Coralville, IA) in combination with MBNL1
immunofluorescence staining, as described previously28, 49.
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For staining of fast myosin heavy chain (MHC), differ-
entiated cultures were fixed with 80% acetone and washed
thoroughly before incubation with primary (MF20, obtained
by D. Fischman, Cornell Medical College, New York, NY)
and secondary Ab (Alexa Fluor 488 goat anti-mouse Ab,
ThermoFisher Scientific, Waltham, MA). Nuclei were
visualized with Hoechst 33258 dye. The samples were
examined with an Olympus AX70 immunofluorescence
microscope. Images were recorded on an Olympus XM10
camera and processed using the Olympus CellSens Stan-
dard 1.8.1 software.
Skeletal muscle fibroblasts were fixed in 4% paraf-
ormaldehyde, permeabilized with 0.4% Triton in PBS
(GIBCO, ThermoFisher Scientific, Waltham, MA) and
incubated with Normal Goat Serum (NGS, Dako, Santa
Clara, CA). Subsequently, cells were incubated with primary
Abs for Desmin (clone D33, Dako, Santa Clara, CA),
Smooth Muscle Actin (clone 1A4, Sigma-Aldrich, Saint
Louise, MO) and Vimentin (clone V9, Sigma-Aldrich, Saint
Louise, MO) and Alexa Fluor 488 secondary Ab (Molecular
Probes, Eugene, OR). Nuclei were counterstained with Dapi
(Molecular Probes, Eugene, OR). All Abs were diluted in
PBS containing 2% Bovine Serum Albumin (BSA, Sigma-
Aldrich, Saint Louise, MO). Random images were acquired
using an Olympus IX51 microscope equipped with an
Olympus TH4-200 camera and Cell F 2.8 software
(Olympus software imaging solution). All images were
evaluated in blind by at least two investigators.
Western blot analysis
Cells were lysed in RIPA buffer (140mM NaCl, 3mM
MgCl2, 1mM EDTA, and 15mM HEPES, pH 7.2, 0.5%
sodium deoxycholate, 1% NP-40, and 0.1% SDS) supple-
mented with a cocktail of protease inhibitors (Roche,
Sigma-Aldrich, St. Louis, MO). Western blots were carried
out using horseradish-peroxidase-conjugated goat anti-
rabbit and anti-mouse Abs (Santa Cruz Biotechnology,
Santa Cruz, CA) and revealed with a chemiluminescence
detection system by Cyanagen (Bologna, Italy). Rabbit
polyclonal Abs to ASB2 and to CDC42 were
purchased from Novus Biologicals (Littleton, CO) and from
Santa Cruz Biotechnology (Santa Cruz, CA), respectively.
Abs to vinculin (clone VIN-11-5) and β-actin (clone AC-74)
were purchased from Sigma-Aldrich (St. Louis, MO).
Imaging and quantitation of the bands were carried out by
the ChemiDoc XRSWestern Blot Imaging System using the
ImageLab 4.0 software (Bio-Rad, Hercules, CA).
Luciferase reporter assay
To construct the ASB2-wt and ASB2-mut luciferase
reporter plasmids, 80nt synthetic oligos (Supplementary
Table S6) encompassing the predicted miR-29c target
sites (wt) or the same mutated sequence (mut, G→ T,
C→G and C→A) of ASB2 3′UTR were synthesized
(Eurofins Genomics, Milan, IT) and cloned into the
SpeI and HindIII restriction sites of the pMIR-
REPORT Luciferase vector (Ambion, ThermoFisher
Scientific, Waltham, MA). For the expression of
luciferase reporter constructs, 7 × 103 HEK-293
cells were plated on 96-multiwell plates and trans-
fected, using the FuGENE® HD transfection reagent
(Promega; Madison, WI), with 7.5 ng of pMIR-Report
plasmids and 45 ng of miR-29c or scramble sequence
expressing plasmids, along with 7.5 ng of pRL plasmid
coding for renilla luciferase (accession number
AF025844, Promega, Madison, WI) to normalize for
transfection efficiency. The luciferase activity was mea-
sured using Dual-Glo Luciferase Assay System kit
(Promega, Madison, WI) and the luminescence was
recorded by VarioskanLux (ThermoFisher Scientific,
Waltham, MA) luminometer. Each experiment was
performed in quadruplicate.
Statistical analysis
GraphPad Prism v.4.03 software (GraphPad Software
Inc., San Diego, CA) was used for statistical analysis.
Continuous variables were analyzed by Student’s t-test,
Welch’s t-test, Mann–Whitney test or ANOVA, as
opportune. All statistical tests were performed two-sided
and a P < 0.05 was considered as statistically significant.
Continuous variables were expressed as mean ± standard
error of the mean (SEM).
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